Epilepsy Drugs Market: Estimates and Forecasts by 2020

Epilepsy is a group of neurological disorders that result in the experience of seizures. The epileptic seizures range from being unrecognized and undetectable to severe shaking and clenching that sometimes causes damage to teeth, bleeding due to biting of tongue and muscle pain. There are three primary types of seizures that are generalized, focal and mal seizures. Generalized seizures affect the complete body and most episodes showcase stiffening or rhythmic movement of limbs and loss of breath due to unresponsive pulmonary function. Partial or focal seizures affect only part or parts of the body and petit mal seizures affect mostly children and can occur several times in a day without risk. Epilepsy is clinically associated with presence of excessive and abnormal cortical nerve cell activity in the brain. Currently there is no known fixed cause of seizures however certain stimulus such as bright strobe lights, camera flashes, heat and stress can cause an epileptic episode in several patients. In addition, low oxygen during birth, brain tumors; brain infections such as meningitis or encephalitis and head injury are also linked significantly to epileptic attacks.

For Full Report And Request TOC@ http://www.sa-brc.com/Global-Epilepsy-Drugs-Market-Assessment--Forecast-2016---2020/upcomingdetail27

Although the symptoms of a seizure may affect any part of the body, the electrical events that produce the symptoms occur in the brain. The location of that event, how it spreads and how much of the brain is affected, and how long it lasts all have profound effects. Electroencephalography, magnetic resonance imaging and computed tomography are the three foremost methods of detecting epilepsy. Even during these diagnostic processes, a patient who is momentarily normal is stimulated to show an epileptic seizure in order to confirm the presence of the condition. There are over 500,000 people suffering from epilepsy in the United Kingdom and approximately 3.5 million affected in United States. According to published research through pubmed, CDC and other sources, there are approximately 20 million people affected with epilepsy throughout the world with over 50,000 new cases each year. The adoption and penetration of third-generation antiepileptic drugs (AEDs), such as eslicarbazepine acetate (Zebinix/Stedesa), lacosamide (Vimpat), perampanel (Fycompa), and ezogabine/retigabine (Potiga/Trobalt), will be a major contributor to such growth. Ongoing research estimates suggest Eisai to be a market leader in epilepsy drugs and is capable of leading for the forecast period. Late stage pipeline for epilepsy drugs has subsided, however a strong stage II pipeline and growing incidence of epilepsy diagnosed around the world is expected to propel the market in coming years. The notable candidates in pipeline are brivaracetam, ganaxolone, VX-765 by Vertex Pharmaceuticals, carisbamate and naluzotan. There are approximately 24 drugs approved by the United States FDA for epilepsy.

In terms of geography, current ongoing research estimates suggest the market is led by North America, where diagnosis rate has traditionally been the highest. This report analyzes six geographies of North America, Europe, Asia-Pacific, Latin America, Middle-East and Africa. This report will provide qualitative analysis for market segmentation, treatment algorithms, drivers and inhibitors, opportunities (organic and non-organic), pipeline analysis and the competitive landscape of the market. Along with this quantitative analysis will be provided for treatment by disease segments and geography.

More Research Reports@ http://www.sa-brc.com/register.php

About Us
Spearhead Acuity Business Research & Consulting Private Limited (OPC) is a premium Life Science business intelligence and data analytics firm. SA-BRC team offers a wide range of business intelligence services to multiple stakeholders such as Medical Device Manufacturers, Service Providers (Hospitals, Payers, etc.), Suppliers, Group Purchase Organizations, Distributors and all other individuals in the entire value chain of healthcare industry. Our research and consulting capabilities extend across several sub-domains within the sphere of Life Sciences such as Biotechnology, Healthcare IT, Medical Devices, Veterinary Sciences, Wellness Products and Pharmaceuticals.

Contact Us
10685-B Hazelhurst Drive
Suite 17411
Houston, TX 77043
United States
Phone: +1(832)-426-3701
E-mail: support@sa-brc.com

This release was published on openPR.